Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (148)	5/22/2002 8:51:03 PM
From: wolfdog2	Respond to of 201

tuck, these seem to be blockbuster results. Let's hope they result in higher sales.

To: tuck who wrote (148)	5/22/2002 8:53:58 PM
From: scott_jiminez	Read Replies (1) \| Respond to of 201

Amazing amount of hype for a single journal article... Let's see, how many red-flags-of-hype can I spot in a single sentence: the first... 1. 'the innovator' 2. 'and global leader' 3. 'the publication of a significant Mayo Clinic Study' 4. 'demonstrating the importance of the company's...' 5. 'the peer-reviewed journal' I recall with clarity the warning from a biochem. professor in grad. school that whenever someone use the phrase 'peer-reviewed journal'...run like hell. I see no evidence in this press release that contradicts that insight. I also see no mention either that Hypertension Diagnostics also has a non-invasive, FDA-approved device for measuring cardiovascular status that is more accurate and more reproducible than impedance cardiography. It takes less time (30 seconds) and is less costly as well. The fact that CDIC only referred to 'traditional management by high blood pressure specialist physicians' as their reference group, and not HDII's CVProfilor device, which is their TRUE competition, speaks volumes about CDIC. In short, CDIC doesn't want to cite HDII because they know that even a brief reference to their main competitor would be an acknowledgement of direct competition. HDII's waveform analysis is, at a minimum, an approach to cardiovascular screening that provides an equal degree of assessment as CDIC. In fact, substituting CDIC's 'BioZ' with HDII's 'CVProfilor' in the article would produce an even greater wealth of data than the over-hyped claims of CDIC's PR dept. And Hypertension Diagnostics, who had ELEVEN abstracts involving its device at a recent hypertension meeting, is not a company SO insecure that it feels the need to issue a separate press release every time an article gets published in a 'peer-reviewed' journal.